The sense of 'betrayal' over Sir Michael Rawlins appointment as a board member of a biotech firm is funny and sad.
Apparently people believe that Sir Michael, who chaired Britain's NICE organization, did so because he hated drug profits and drug companies.
Sir Michael has been a pioneer in promoting personalized medicine and finding ways to reduce the time and cost of medical innovation as a way of making medicines more affordable.
The failure of his critics to understand this is based in ignorance and ideology. So is their belief that he was a leader in vanguard against commercialization.
